Company intelligence
AcuCort AB
We make good drugs better
About AcuCort AB
AcuCort has developed and commercializes Zeqmelit™, a new fast-dissolving oral film to put on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV) and for the treatment of patients with COVID-19 who need supplemental oxygen therapy. Zeqmelit™ is approved in Sweden, Denmark, and Norway; and AcuCort has signed its first commercial agreement. Altogether, this strengthens the company’s assessment that the time to commercialization may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Please visit www.acucort.se.
Verified activity
Signals from AcuCort AB
3 published signals
Legal & Regulatory
AcuCort AB registered Zeqmelit as a trade mark in Ukraine.
Reported by AcuCort AB
Presence & Recognition
AcuCort AB CEO Jonas Jönmark recently joined Investor Studios’
Reported by AcuCort AB
Research & Knowledge
AcuCort AB published its August 2026 newsletter highlighting two scientific articles published in the peer-reviewed Journal of Market Access & Health Policy.
Reported by AcuCort AB